This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Transseptal VIV Edwards SAPIEN 3® TMVR

Tuesday, February 18, 2020

Hysi I, Fabre O, Pecheux M, et al. Transseptal VIV Edwards SAPIEN 3® TMVR. February 2020. doi:10.25373/ctsnet.11837382

The authors were faced with a patient who had previous double aortic and mitral valve replacements with two bioprosthesis (Perimount aortic 25 mm and Perimount mitral 29 mm) and presented with double structural valve degeneration. The patient was a 78-year-old woman who had major dyspnea and presented in 2019 with several hospitalizations for left heart failure. Surgery was considered of high risk. The heart team decided on a staged procedure for double endovascular treatment with aortic TAVR and transseptal TVMR.

In the following video, the authors briefly show the aortic TAVR and the transseptal VIV Edwards SAPIEN 3® TMVR. The aortic TAVR was done with a Medtronic COREVALVE of 26 mm and the mitral TVMR was done with an Edwards SAPIEN 3 29 mm. The final result was optimal with no mitral or aortic regurgitation and with very low mean gradients.


The information and views presented on represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Add comment

Log in or register to post comments